stoxline Quote Chart Rank Option Currency Glossary
  
(IMMU)
  0 (0%)    03-28 09:09
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-03-28 8:46:32 AM
Short term     
Mid term     
Targets 6-month :  12.2 1-year :  14.25
Resists First :  10.44 Second :  12.2
Pivot price 10.31
Supports First :  10.24 Second :  10.11
MAs MA(5) :  10.37 MA(20) :  10.27
MA(100) :  10 MA(250) :  9.82
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  67.1 D(3) :  73.9
RSI RSI(14): 57.9
52-week High :  10.44 Low :  8.6
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MMU ] has closed below upper band by 29.8%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.39 - 10.43 10.43 - 10.48
Low: 10.18 - 10.22 10.22 - 10.27
Close: 10.29 - 10.36 10.36 - 10.44
Company Description

Headline News

Thu, 21 Mar 2024
Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher - Yahoo Movies Canada

Fri, 02 Feb 2024
PTI local leader Imran Immu shot dead in Abbottabad - Pakistan Observer

Tue, 16 Jan 2024
Data haul improves immunotherapy response prediction | VUMC Reporter | Vanderbilt University - VUMC Reporter

Thu, 28 Dec 2023
When Will Mendus AB (publ) (STO:IMMU) Breakeven? - Simply Wall St

Fri, 14 Jan 2022
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade ... - VUMC Reporter

Thu, 14 Oct 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma ... - ScienceDirect.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
Sector:
Industry:
Shares Out 55 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 64.6 (%)
Shares Short 21 (K)
Shares Short P.Month 40 (K)
Stock Financials
EPS 0.43
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.46
Profit Margin 84.1 %
Operating Margin 77.8 %
Return on Assets (ttm) 1.8 %
Return on Equity (ttm) 4.6 %
Qtrly Rev. Growth 11.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.58
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 39 (M)
Levered Free Cash Flow 22 (M)
Stock Valuations
PE Ratio 23.56
PEG Ratio 0
Price to Book value 0.9
Price to Sales 17.73
Price to Cash Flow 14.49
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android